QuidelOrtho Corporation Completes Acquisition of LEX Diagnostics

Rhea-AI Summary

QuidelOrtho (Nasdaq: QDEL) completed the acquisition of LEX Diagnostics for approximately $100 million on April 20, 2026, adding the FDA 510(k)-cleared and CLIA-waived LEX VELO System. The cartridge-based ultra-fast PCR platform delivers multiplex Influenza A/B and COVID-19 results in about six to ten minutes and is slated for a U.S. commercial launch later in 2026, with global expansion subject to local approvals. The deal expands QuidelOrtho's point-of-care molecular diagnostics portfolio and complements its immunoassay, clinical chemistry and transfusion medicine offerings.

Positive

• $100 million acquisition expands molecular diagnostics portfolio
• LEX VELO received FDA 510(k) clearance and CLIA waiver (Feb 2026)
• Ultra-fast PCR: results in ~6–10 minutes from swab
• U.S. commercial launch planned later in 2026

Negative

• Transaction used approximately $100 million cash consideration
• Global rollout subject to local regulatory approvals, could delay expansion

News Market Reaction – QDEL

+1.42%

31 alerts

+1.42% Session close to close

-11.6% Trough in 27 hr 57 min

$915.02M Market Cap

0.4x Rel. Volume

In the Apr 20 session, QDEL gained 1.42%, reflecting a mild positive market reaction. Argus tracked a trough of -11.6% from its starting point during tracking. Our momentum scanner triggered 31 alerts that day, indicating elevated trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights QuidelOrtho’s completion of the LEX Diagnostics acquisition for about $...

Analysis

This announcement highlights QuidelOrtho’s completion of the LEX Diagnostics acquisition for about $100 million, adding the LEX VELO ultra-fast PCR system, which can deliver results in six to ten minutes. It advances the company’s point-of-care molecular diagnostics strategy following recent pressured financial updates, including preliminary Q1 2026 revenue of $615–$620M. Investors may focus on how this platform contributes to growth, margins, and future earnings calls, alongside ongoing leadership transitions and capital allocation decisions.

Key Figures

Acquisition price: $100 million Time to result: Approximately ten minutes or less Testing time range: Six to ten minutes

3 metrics

Acquisition price $100 million Cash consideration for LEX Diagnostics acquisition

Time to result Approximately ten minutes or less LEX VELO System point-of-care PCR platform

Testing time range Six to ten minutes RT‑PCR for Influenza A, Influenza B and COVID‑19

Historical Context

5 past events · Latest: Apr 15 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 15	Prelim Q1 revenue	Negative	-27.5%	Weaker respiratory season and regional disruptions drove negative revenue update.
Mar 24	Leadership appointment	Neutral	-2.3%	New Chief Legal Officer announced amid broader company transition in legal roles.
Feb 19	Educational content release	Neutral	-2.3%	Science podcast episode on high‑sensitivity troponin and cardiac diagnostics trends.
Feb 18	Conference presentation	Neutral	-2.3%	Planned appearance at Raymond James investor conference announced to the market.
Feb 11	Earnings and guidance	Negative	-17.6%	FY25 results with goodwill impairment and FY26 guidance led to a sharp selloff.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows QDEL often selling off on material financial updates, with large negative moves around earnings and guidance, while more routine or strategic communications have also coincided with modest declines.

Recent Company History

Over the last six months, QuidelOrtho’s major news flow has been dominated by financial and leadership developments. An earnings release on Feb 11, 2026 highlighted $2.73B FY25 revenue but also a $701M goodwill impairment and a FY25 GAAP net loss of $1.13B, followed by a -17.59% move. Preliminary Q1 2026 revenue of $615–$620M and negative free cash flow of $(65)–$(70)M on Apr 15, 2026 preceded a sharper -27.47% reaction. Against this backdrop of pressured financial sentiment, the LEX acquisition represents a strategic expansion in molecular diagnostics.

Key Terms

in vitro diagnostics, molecular diagnostics, rt-pcr, 510(k) clearance, +4 more

8 terms

in vitro diagnostics medical

"QuidelOrtho, a global leader of innovative in vitro diagnostics, announced today..."

In vitro diagnostics are medical tests performed on samples taken from the body—such as blood, urine or tissue—using instruments or kits outside the patient to detect disease, measure biomarkers or guide treatment decisions. They matter to investors because sales, regulatory approvals, reimbursement rules and adoption rates drive companies’ revenue and margins much like product launches and consumer demand in other industries; advances can create growth or disruption in healthcare markets.

molecular diagnostics medical

"growth in point-of-care molecular diagnostics –– Expands Portfolio..."

Molecular diagnostics are laboratory tests that look for specific molecules — such as genes, pieces of DNA or RNA, or proteins — to detect disease, predict risk, or guide treatment choices. For investors, these tests matter because they can change how illnesses are diagnosed and treated, create recurring revenue through specialized tests and companion products, and face clear regulatory and reimbursement pathways that drive commercial value; think of them as reading a biological barcode to inform medical decisions.

rt-pcr medical

"multiplex RT-PCR testing for Influenza A, Influenza B and COVID-19..."

RT-PCR is a laboratory test that converts a tiny amount of genetic material from a sample into many copies so specific viral or genetic targets can be detected, like photocopying one page until you have enough to read clearly. For investors, RT-PCR matters because its accuracy, capacity, and regulatory approval drive demand for diagnostic equipment, testing services, and related supply chains, and can influence revenue and market sentiment around healthcare and biotech companies.

510(k) clearance regulatory

"The LEX VELO System received U.S. Food and Drug Administration ("FDA") 510(k) clearance..."

A 510(k) clearance is a U.S. regulatory approval that lets a medical device be sold because it is shown to be substantially similar to an already-legal device; think of it as a passport saying the new product is close enough to a known item to enter the market without a full, lengthy review. For investors, 510(k) clearance signals faster, lower-cost market access and reduced regulatory risk compared with new, untested device pathways, which can materially affect timelines, costs and revenue prospects.

clia waiver regulatory

"The LEX VELO System received...510(k) clearance and CLIA waiver in February 2026."

A CLIA waiver is an official permission that lets a medical test be performed outside specialized laboratories—such as in a doctor’s office, pharmacy, or clinic—because the test is simple, safe, and unlikely to give wrong results. For investors, a waiver often means a much larger, faster market rollout and lower costs for adoption, similar to a consumer product moving from specialty stores onto supermarket shelves.

point-of-care medical

"accelerate growth in Point-of-Care Molecular Diagnostics –– Expands Portfolio..."

"Point-of-care" refers to the location where immediate decision-making or actions happen, often involving the direct delivery of services or results. In healthcare, it describes tests or treatments performed directly at the patient's side, rather than in a distant laboratory. For investors, understanding "point-of-care" highlights the convenience, speed, and potential growth opportunities of services or products that bring solutions directly to the user or patient.

multiplex medical

"deliver highly sensitive, multiplex RT-PCR testing for Influenza A..."

A multiplex is a laboratory test or diagnostic method that detects or measures several different targets at the same time from a single sample, like checking for multiple ingredients in one recipe rather than cooking separate dishes. For investors, multiplex technologies can lower testing costs, speed results, and expand market reach because one product can serve multiple purposes, affecting revenue potential, production scale, and regulatory review paths.

cartridge-based technical

"Its proprietary cartridge-based design supports rapid clinical decision-making..."

A cartridge-based product uses disposable, pre-loaded cartridges or pods that contain the active materials needed for each use — for example reagents in a diagnostic test or ink in a printer — while the main machine performs the work. For investors this matters because the business model often earns repeat revenue from consumable cartridge sales, can simplify user adoption (think coffee pods vs. loose grounds) and create switching costs or margins that affect long‑term growth and valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

– Marks a Milestone in QuidelOrtho's Plans to Accelerate Growth in Point-of-Care Molecular Diagnostics –
– Expands Portfolio with Ultra-Fast PCR Platform Designed to Deliver Results in Approximately Ten Minutes or Less –
– Company Expects to Initiate U.S. Commercial Launch of the LEX VELO System Later This Year –

SAN DIEGO, April 20, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, announced today it has completed the acquisition of LEX Diagnostics ("LEX") for cash consideration of approximately $100 million. The LEX VELO System received U.S. Food and Drug Administration ("FDA") 510(k) clearance and CLIA waiver in February 2026.

The LEX VELO System is a breakthrough molecular diagnostics platform that is designed to deliver highly sensitive, multiplex RT-PCR testing for Influenza A, Influenza B and COVID-19 directly from a swab sample in approximately six to ten minutes. Its proprietary cartridge-based design supports rapid clinical decision-making in decentralized care environments by eliminating the need for external liquid handling; delivering speed, reliability and ease of use. The acquisition of LEX marks a critical milestone in QuidelOrtho's molecular diagnostics strategy to accelerate its growth in point-of-care molecular diagnostics by acquiring innovative technology within one of the fastest-growing segments of the diagnostics market.

"The FDA clearance of the LEX VELO System and the completion of our acquisition of LEX mark a pivotal moment for QuidelOrtho and for our customers," said Brian J. Blaser, President and Chief Executive Officer of QuidelOrtho. "This ultra-fast PCR platform is designed to deliver lab-quality results in minutes and fits seamlessly into point-of-care workflows. It empowers providers to act faster, make better-informed decisions and ultimately improve patient outcomes. It also reflects our long-term commitment to bringing advanced diagnostics closer to the patient."

Completing the acquisition of LEX expands QuidelOrtho's molecular diagnostics portfolio while complementing the Company's leadership positions in immunoassay, clinical chemistry and transfusion medicine. It reinforces QuidelOrtho's ability to deliver integrated diagnostic solutions across the continuum of care, from point of care to hospital, lab to clinic.

"LEX achieved an extraordinary milestone with FDA clearance and CLIA waiver of the LEX VELO System," said Ed Farrell, Chief Executive Officer of LEX. "We are proud to join QuidelOrtho and to bring this technology to customers worldwide. We believe we can redefine what is possible in point-of-care molecular diagnostics."

QuidelOrtho expects to initiate the U.S. commercial launch of the LEX VELO System later this year. Global expansion is expected to follow, subject to local regulatory approvals.

QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook and X.

About QuidelOrtho Corporation
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are any statement contained herein that is not strictly historical, including, but not limited to, QuidelOrtho's commercial and other strategic goals, and other future plans, objectives, strategies, expectations and intentions. Without limiting the foregoing, the words "may," "will," "could," "would," "should," "might," "expect," "anticipate," "believe," "estimate," "plan," "intend," "goal," "project," "strategy," "future," "continue," "aim," "strive," "seek" or similar words, expressions or the negative of such terms or other comparable terminology are intended to identify forward-looking statements. Such statements are based on the beliefs and expectations of QuidelOrtho's management as of the date of this press release and are subject to significant known and unknown risks and uncertainties. Actual results or outcomes may differ significantly from those set forth or implied in the forward-looking statements. The following factors, among others, could cause actual results or outcomes to differ from those set forth or implied in the forward-looking statements: fluctuations in demand for QuidelOrtho's non-respiratory and respiratory products; supply chain, production, logistics, distribution and labor disruptions and challenges, including disruptions and challenges related to the 2026 Middle East conflict; inability to successfully identify, consummate or realize the anticipated benefits of strategic transactions, strategic restructurings, divestitures, spin-offs or discontinuances of certain business operations, or debt financings, on the anticipated timelines, or at all; delays in the development of or failures or delays in the receipt of approvals for new or enhanced products; failure of new products and services to be commercially viable or accepted; changes in reimbursement rates for QuidelOrtho's products, including reimbursement rate reductions proposed by the China National Health Security Administration; and other macroeconomic, geopolitical, market, business, competitive and/or regulatory factors affecting the business of QuidelOrtho generally, including those arising from the effects of announced or future or amended tariffs, trade policies, investigations and global trade relations, as well as those discussed in QuidelOrtho's Annual Report on Form 10-K for the fiscal year ended December 28, 2025 and subsequent reports filed with the Securities and Exchange Commission, including under Part I, Item 1A, "Risk Factors" of the Form 10-K. You should not rely on forward-looking statements as predictions of future events because these statements are based on assumptions that may not come true and are speculative by their nature. All forward-looking statements are based on information currently available to QuidelOrtho and speak only as of the date of this press release. QuidelOrtho undertakes no obligation to update any of the forward-looking information or time-sensitive information included in this press release, whether as a result of new information, future events, changed expectations or otherwise, except as required by law.

Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
IR@QuidelOrtho.com

Media Contact:
Stephanie Kleewein
Senior Corporate Communications and PR Manager
media@QuidelOrtho.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/quidelortho-corporation-completes-acquisition-of-lex-diagnostics-302746364.html

SOURCE QuidelOrtho Corporation

FAQ

What did QuidelOrtho (QDEL) acquire on April 20, 2026?

QuidelOrtho acquired LEX Diagnostics for approximately $100 million. According to the company, the acquisition adds the FDA 510(k)-cleared, CLIA-waived LEX VELO System to QuidelOrtho's point-of-care molecular diagnostics portfolio.

What is the LEX VELO System and how fast are results?

The LEX VELO System is an ultra-fast, cartridge-based PCR platform delivering results in about six to ten minutes. According to the company, it provides multiplex RT-PCR for Influenza A, Influenza B and COVID-19 directly from a swab.

When will QuidelOrtho (QDEL) commercially launch the LEX VELO System in the U.S.?

QuidelOrtho expects a U.S. commercial launch later in 2026. According to the company, the launch follows FDA clearance and CLIA waiver and precedes planned global expansion pending local approvals.

How was the LEX VELO System regulated before acquisition by QuidelOrtho?

The LEX VELO System received FDA 510(k) clearance and a CLIA waiver in February 2026. According to the company, those clearances enable point-of-care use and support the planned commercial rollout.

What financial impact does the LEX acquisition have on QuidelOrtho (QDEL)?

QuidelOrtho completed the acquisition for approximately $100 million in cash. According to the company, the transaction expands product offerings but represents an immediate cash outflow of roughly $100 million.